openPR Logo
Press release

Synovial Sarcoma Therapeutics - Key Players Analysis Takara Bio Inc., Oncolytics Biotech Inc., Cue Biopharma

12-13-2018 06:49 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: P&S Intelligence

Synovial Sarcoma Therapeutics - Key Players Analysis Takara Bio

The study analysed that the Synovial sarcoma pipeline comprises of 22 drug candidates in different stages of development.

Synovial sarcoma is rare type of cancer and approximately one to three people in one million people are diagnosed with synovial sarcoma every year, globally. The disease occurs frequently in young adults; however, the disease can affect a person at any age. Synovial sarcoma is more common in males, and the male to female ratio of the disease stands at 12 males for every 10 females. Various new therapies and advanced technologies are driving the growth of Synovial sarcoma pipeline.

Browse report sample at: https://www.psmarketresearch.com/market-analysis/synovial-sarcoma-therapeutics-pipeline-analysis/report-sample

New innovating technologies offer development of promising drugs

Many technologies such as REOLYSIN technology, ZVex and GLAAS technology, Laser Micro-beam Microdissection are being developed that can bring the innovative treatment, which can control the progression of Synovial sarcoma. ZVex and GLAAS are complementary discovery platforms designed to activate and expand the immune system’s natural ability to create tumour-specific cytotoxic T cells (CTLs) in vivo.

Browse report at: https://www.psmarketresearch.com/market-analysis/synovial-sarcoma-therapeutics-pipeline-analysis

*Major companies collaborate for the development of Synovial Sarcoma Pipeline

The research also found that various companies have collaborated for the development of Synovial sarcoma pipeline. In February 2014, Pfizer Inc. (Pfizer) and Merck & Co., Inc. (Merck) agreed to explore the therapeutic potential of Merck’s investigational anti-PD-1 therapy, MK-3475, in combination with two of the Pfizer’s oncology assets.

Pre-Purchase Inquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=synovial-sarcoma-therapeutics-pipeline-analysis

Some of the key players developing drugs for Synovial sarcoma include Takara Bio Inc., Oncolytics Biotech Inc., Accuronix Therapeutics, Inc., Cue Biopharma, Inc. and others.

About P&S Intelligence

P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.

Contact:
P&S Intelligence
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Synovial Sarcoma Therapeutics - Key Players Analysis Takara Bio Inc., Oncolytics Biotech Inc., Cue Biopharma here

News-ID: 1436962 • Views: 641

More Releases from P&S Intelligence

SD-WAN Market to Register 38.6% CAGR during 2020-2030
The software-define wide area network (SD-WAN) market is expected to advance at a CAGR of 38.6% during the forecast period (2020-2030). At this rate, the market is expected to reach $43.0 billion by 2030 from $1.4 billion in 2019. The key factors driving the market growth include increasing penetration of internet, surging adoption of bring-your-own-device (BYOD) policy at workplaces, rising need for simplified enterprise network architecture, growing utilization of data
AI in Agriculture Market To Value $8,379.5 Million in 2030
The rising demand for agricultural production is leading to the increasing adoption of drone analytics, internet of things (IoT) devices, and livestock monitoring techniques by farmers. These factors are projected to lead to an increase in the revenue of the artificial intelligence (AI) in agriculture market from $852.2 million in 2019 to $8,379.5 million in 2030, at a 24.8% CAGR during 2020-2030 (forecast period). The need for AI among farmers
Temperature Sensor Market Is on the Track To Reach $11.1 Billion Worth by 2030
A temperature sensor is a measures temperature by an electrical signal using a thermocouple or resistance temperature detector. The global temperature sensor market is predicted to hit $11.1 billion in 2030. Due to rising smartphone sales and increasing demand from the automobile industry, the market is growing. Moreover, resistance temperature detectors (RTDs), which are very pure conducting metals coiled into coils like platinum, copper, or nickel, are accurate temperature sensors. In
Increase in Construction Activities Boost Commercial AC Market
The commercial AC market is expected to register a sale of 25.4 million units by 2030, due to the worldwide rise in the number of construction projects and the increase in disposable income of the people. In addition, the variable refrigerant flow systems (VRF), which were first patented by Daikin as Variant Refrigerant Volume, are expected to experience the highest sales in the near future, attributed to in-expensive and energy-efficient

All 5 Releases


More Releases for Synovial

Synovial Sarcoma Treatment Market Revenue Opportunies By Key Vendors Synovial Sa …
Synovial sarcoma consists of abnormal growth of soft-tissue. Synovial sarcoma is a rare type of cancer and is more prevalent in teenagers and young adults. Synovial sarcoma is highly metastatic and spreads to other places, in almost 50% of the cases and lungs are the common site for metastasis to occur. The cause behind occurrence of synovial sarcoma have not yet been established, however, it is found to be associated
Synovial Sarcoma Treatment Market - Global Industry Insights, Trends, 2026
Synovial sarcoma consists of abnormal growth of soft-tissue. Synovial sarcoma is a rare type of cancer and is more prevalent in teenagers and young adults. Synovial sarcoma is highly metastatic and spreads to other places, in almost 50% of the cases and lungs are the common site for metastasis to occur. The cause behind occurrence of synovial sarcoma have not yet been established, however, it is found to be associated
Synovial Sarcoma - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Synovial Sarcoma - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Synovial Sarcoma - Pipeline Review, H2 2017, provides an overview of the Synovial Sarcoma (Oncology) pipeline landscape. Synovial sarcoma is a soft tissue tumor occurring in the biphasic or monophasic type and consisting of epithelial and/or
Synovial Sarcoma Market Forecast Research Reports Offers Key Insights
Synovial sarcoma is a predominantly juxta-articular, malignant, and soft-tissue tumour, which represents approximately 10% of all soft-tissue sarcomas. It was first reported in 1893, and due to its resembling characteristic with synovium, it was named as synovial sarcoma. As per the studies it has been observed that, synovial sarcomas are slow growing tumours and usually occur predominantly around knees, followed by the ankle, shoulder and elbow. Rise in incidence rate
Synovial Sarcoma Pipeline Insight and Therapeutic Assessment Reviewed in 2017
Market Research Hub's latest Pharmaceutical and “Healthcare disease pipeline guide Synovial Sarcoma Pipeline Review”, H2 2017, provides an overview of the Synovial Sarcoma (Oncology) pipeline landscape. Request For Free Sample - http://www.marketresearchhub.com/enquiry.php?type=S&repid=1305536 Synovial sarcoma is a soft tissue tumor occurring in the biphasic or monophasic type and consisting of epithelial and/or spindle cell components. Symptoms include swelling, mass that may or may not be accompanied by pain and limping or difficulty
Synovial Sarcoma Pipeline Insight and Therapeutic Assessment 2017
Market Research Hub (MRH) has recently broadcasted a new study to its broad research portfolio, which is titled as “Synovial Sarcoma-Pipeline Insights, 2017, report provides comprehensive insights of the ongoing therapeutic research and development across Synovial Sarcoma. The report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products. A comparative pipeline therapeutics assessment of Synovial Sarcoma by development stage, therapy type, route of administration